Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03582774 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy

Study acronym: PSMA SRT
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jul 12, 2026 to Jul 12, 2027
    • Study completion date: Jul 12, 2027 to Jul 12, 2028
    v20
  2. Primary completion date: Jul 12, 2025 to Jul 12, 2026
    • Study completion date: Jul 12, 2026 to Jul 12, 2027
    v19
  3. Primary completion date: Jul 12, 2024 to Jul 12, 2025
    • Study completion date: Jul 12, 2025 to Jul 12, 2026
    v18
  4. Re-verified, no change to tracked fieldsv17
  5. Primary completion date: Jul 12, 2023 to Jul 12, 2024
    • Study completion date: Jul 12, 2024 to Jul 12, 2025
    v16
Show 14 earlier versionsHide 14 earlier versions
  1. 3 versions Re-verified since Oct 28, 2021, no change to tracked fieldsv13-v15
  2. Primary endpoint revisedv12 Show 9 more changesShow less
    • Study sites: 1 to 2
    • Primary completion date: Sep 2023 to Jul 12, 2023
    • Study completion date: Jul 2024 to Jul 12, 2024
    • Interventions: 68Ga-PSMA-11 (Drug) to Best Practice (Other), Computed Tomography (Procedure), Gallium Ga 68-labeled PSMA-11 (Radiation), Positron Emission Tomography (Procedure)
    • Eligibility criteria shortened, about 9 words
    • Secondary endpoints: 3 to 4
    • Study description shortened, about 300 words
    • Collaborators expanded, about 4 words
    • Study title shortened, about 2 words
  3. Re-verified, no change to tracked fieldsv11
  4. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v10
  5. Collaborators shortened, about 4 wordsv9
  6. 3 versions Re-verified since Nov 7, 2019, no change to tracked fieldsv6-v8
  7. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 1, 2018 to Jul 12, 2018
    v5
  8. Re-verified, no change to tracked fieldsv4
  9. Start date: Jul 30, 2018 to Sep 1, 2018
    • Primary completion date: Jul 30, 2023 to Sep 2023
    • Study description expanded, about 250 words
    v3
  10. Primary completion date: Jul 1, 2023 to Jul 30, 2023
    • Start date: Jul 1, 2018 to Jul 30, 2018
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase III trial studies how well Gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) positron emission tomography (PET)/computed tomography (CT) works in diagnosing participants with prostate cancer that has come back after surgery. 68Ga-PSMA-11 are taken up by cancer cells. Diagnostic procedures, such as PET/CT scans, may help find and diagnose prostate cancer and find out how far the disease has spread. Giving 68Ga-PSMA-11 with PET/CT may help doctors plan better for salvage radiation therapy in participants with recurrent prostate cancer.
Trial Details
NCT Number NCT03582774
Lead Sponsor Jonsson Comprehensive Cancer Center
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Recurrent Prostate Carcinoma
Related terms Prostatic Neoplasms
Enrollment 193 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov